Bausch Health Companies Inc. (BHC) Fair Value 2026

BHC · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 5 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, Bausch Health Companies Inc. (BHC) trades at $6.30, versus a $23.22 median fair value across its 5 active models — 268.6% above the current price. QOC: 6.8/10. Value Trap Risk: 13/100 (SAFE). 5/13 models active. Within that set, the Bayesian DCF component alone returns $26.87.

Key Facts

Ticker
BHC
Price
$6.30
Quality Score
6.8/10
Value Trap Risk
13/100
Models Active
5/13
Last Updated
Strength: CUCE Ensemble suggests +456.4% upside with 4% confidence
Risk: Limited model coverage (5/13) may reduce confidence

Is Bausch Health Companies Inc. (BHC) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Bausch Health Companies Inc. (BHC) appears undervalued as of : the median of 5 independent fair value estimates is $23.22, 268.6% above the current price of $6.30. Estimates range from $1.02 to $35.05. BHC scores 6.8/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BHC’s +268.6% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bausch Health Companies Inc. Stock in 2026? →

What Fair Value Does Each Model Give BHC?

5 Intrinsic Value Models vs. Current Price ($6.30)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $26.87 +326.5%
Ensemble · Low Conviction
 $35.05 +456.4%
Unlock the Full Matrix

Access 3 additional models including EROIC Spread, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is BHC's Fair Value Range?

Spread across 5 independent models · $1.02 to $35.05

CirclFi's 5 active models place Bausch Health Companies Inc. (BHC) between $1.02 and $35.05 per share, a spread of 147% of the median. The median of that range — $23.22 — is the fair value CirclFi publishes for BHC, against a current price of $6.30.

Low · EROICHigh · CUCE
$1.02median $23.22$35.05
Where the range comes from
Most bearish modelEROIC Spread$1.02
Most bullish modelCUCE$35.05
Model agreement4 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BHC. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BHC, not a CirclFi price target. How each model works →

What Is Bausch Health Companies Inc. (BHC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bausch Health Companies Inc.'s intrinsic value is estimated at a median fair value of $23.22. At a current market price of $6.30, 4 of 5 active valuation models identify upside potential, projecting a median implied return of +268.6%. Notably, CUCE sees the most upside at +456.4% (fair value: $35.05), while EROIC is the most conservative at -83.8% ($1.02). The spread between these extremes — +540.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About BHC?

5 of 13 models are currently active for BHC. Of these, 4 models suggest upside while 1 model suggests overvaluation. Taken together, their median fair value for BHC is $23.22 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $26.87 on its own, implying +326.5% upside from the current price. See which stocks rank higher →

How Does BHC Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, BHC ranks #34 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a healthcare company, Bausch Health Companies Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating BHC should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BHC a Value Trap?

CirclFi's Value Trap algorithm assigns BHC a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Bausch Health Companies Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Bausch Health Companies Inc. is rated at 6.8/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +540.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BHC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BHC's 5 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bausch Health Companies Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

HROWHarrow, Inc.QOC 7.0MRMDMariMed Inc.QOC 6.8TAKTakeda Pharmaceutical Company LimitedQOC 7.0ANIKAnika Therapeutics, Inc.QOC 6.8LQDALiquidia CorporationQOC 7.0TEVATeva Pharmaceutical Industries LimitedQOC 6.7LFCRLifecore Biomedical, Inc.QOC 5.9RAPHRaphael Pharmaceutical Inc.QOC 4.6ANIPANI Pharmaceuticals, Inc.QOC 9.0UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: HROW · MRMD · TAK · ANIK · LQDA · TEVA · LFCR · RAPH · ANIP · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to BHC?

7 companies across all industries closest to BHC’s Quality of Company score of 6.8/10.

COHUCohu, Inc.QOC 6.8VSHVishay Intertechnology, Inc.QOC 6.8BVBrightView Holdings, Inc.QOC 6.8WRLDWorld Acceptance CorporationQOC 6.8GLGIGreystone Logistics, Inc.QOC 6.8CLRICleartronic, Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: COHU · VSH · BV · WRLD · GLGI · CLRI · NVDA

Where Does BHC Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

BHC is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Bausch Health Companies Inc.’s Valuation?

What is Bausch Health Companies Inc.'s intrinsic value in 2026?

CirclFi puts Bausch Health Companies Inc. (BHC)'s intrinsic value at $23.22 — the median of 5 independent model estimates as of 2026-08-27, ranging from $1.02 to $35.05. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $26.87 on its own. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BHC overvalued or undervalued right now?

At $6.30, 4 of 5 active models suggest BHC may be undervalued, while 1 indicate potential overvaluation. The median of all 5 fair value estimates is $23.22, 268.6% above the current price of $6.30 — a consensus view that BHC is undervalued. The assessment depends on which methodology best fits Bausch Health Companies Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.8 mean for BHC?

Bausch Health Companies Inc.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BHC?

CirclFi analyzes BHC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BHC?

Of the 5 models currently active on BHC, CUCE is the most bullish at $35.05 per share, and EROIC Spread is the most bearish at $1.02. CirclFi's published fair value for BHC is the median of that range, $23.22, not either extreme. The gap between the two ends equals 147% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BHC a value trap in 2026?

Bausch Health Companies Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Bausch Health Companies Inc. (BHC) has a median fair value of $23.22 — 268.6% above the current price of $6.30 — as of 2026-08-27.” Source: circlfi.com/stock/BHC/ · Methodology
Primary sources for this BHC valuation
  • Financial statements: Bausch Health Companies Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000885590) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BHC as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on BHC.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for BHC Unlock All 5 — $39/mo